

PATENT APPLICATION

5

CYCLIC SILICON COMPOUNDS

10 **Inventors:** Robert Kuimelis, a citizen of the United States, residing at
785 Montrose Avenue
Palo Alto, CA 94303

15 Glenn McGall, a citizen of Canada, residing at
4644 Doyle Ct.
San Jose, CA 95129

20 **Assignee:** Affymetrix, Inc.
3380 Central Expressway
Santa Clara, CA 95051

25 **Entity:** Large

CYCLIC SILICON COMPOUNDS

FIELD OF THE INVENTION

The present invention relates to silicon based compounds. More particularly, the
5 present invention relates to cyclic silicon compounds.

BACKGROUND OF THE INVENTION

Silylating agents have been developed in the art which react with and coat
surfaces, such as silica surfaces. For example, silylating agents for use in modifying silica
used in high performance chromatography packings have been developed.
10 Monofunctional silylating agents have been used to form monolayer surface coatings,
while di- and tri-functional silylating agents have been used to form polymerized coatings
on silica surfaces. Many silylating agents, however, produce coatings with undesirable
properties including instability to hydrolysis and the inadequate ability to mask the silica
surface which may contain residual acidic silanols.

15 Silylating agents have been developed for the silylation of solid substrates, such
as glass substrates, that include functional groups that may be derivatized by further
covalent reaction. The silylating agents have been immobilized on the surface of
substrates, such as glass, and used to prepare high density immobilized oligonucleotide
probe arrays. For example, N-(3-(triethoxysilyl)-propyl)-4-hydroxybutyramide (PCR
20 Inc., Gainesville, Fla. and Gelest, Tullytown, Pa.) has been used to silylate a glass
substrate prior to photochemical synthesis of arrays of oligonucleotides on the substrate,
as described in McGall et al., J. Am. Chem. Soc., 119:5081-5090 (1997), the disclosure
of which is incorporated herein by reference.


Hydroxyalkylsilyl compounds that have been used to prepare hydroxyalkylated
25 substances, such as glass substrates. N,N-bis(hydroxyethyl) aminopropyl-triethoxysilane
has been used to treat glass substrates to permit the synthesis of high-density
oligonucleotide arrays. McGall et al., Proc. Natl. Acad. Sci., 93:13555-13560 (1996); and
Pease et al., Proc. Natl. Acad. Sci., 91:5022-5026 (1994), the disclosures of which are
incorporated herein. Acetoxypentyl-triethoxysilane has been used to treat glass substrates
30 to prepare them for oligonucleotide array synthesis, as described in PCT WO 97/39151,
the disclosure of which is incorporated herein. 3-Glycidooxy propyltrimethoxysilane has

been used to treat a glass support to provide a linker for the synthesis of oligonucleotides.
EP Patent Application No. 89 120696.3.

Methods have been developed in the art for stabilizing surface bonded silicon compounds. The use of sterically hindered silylating agents is described in Kirkland et al., Anal. Chem. 61: 2-11 (1989); and Schneider et al., Synthesis, 1027-1031 (1990).


SUMMARY OF THE INVENTION

According to one aspect of the present invention, cyclic silanes are presented having the formula



wherein R_1 , R_2 , R_3 and R_4 are independently alkyl, functionalized alkyl, aryl or alkoxy and X , Y and Z are independently a bond, O, S, NR_5 , wherein R_5 is H or alkyl.

In another aspect of the present invention, cyclic silanes are presented having the formula



wherein R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 and R_8 are independently alkyl, functionalized alkyl, aryl or alkoxy and X , Y , Z , W , T and U are independently a bond, O, S, NR_5 , wherein R_5 is H or alkyl.

Other cyclic silanes are also disclosed in accordance with the present invention. Cyclic silanes of N,N-bis(2-hydroxyethyl)-N-(3-triethoxysilylpropyl)amine and N-(2-hydroxyethyl)-N,N-bis(3-trimethoxysilylpropyl)amine are particularly preferred embodiments of one aspect of the present invention.

5 Compositions of matter comprising a substantially pure cyclic silane are also disclosed.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows a ¹³C NMR spectrum of Bis silane.

FIG. 2 shows a ¹H NMR spectrum of Bis silane.

10 FIG 3 shows a ¹³C NMR spectrum of Bis-B silane.

FIG 4 shows a ¹H NMR spectrum of Bis-B silane

FIG 5 shows a GC/MS ion chromatogram of Bis silane.

FIG 6 shows a GC/MS ion chromatogram of Bis B silane

FIG 7 shows the cyclic structure of Bis and Bis B silane.

DETAILED DESCRIPTION OF THE INVENTION

15 The present invention has many preferred embodiments and relies on many patents, applications and other references for details known to those of the art. Therefore, when a patent, application, or other reference is cited or repeated below, it should be understood that it is incorporated by reference in its entirety for all purposes as well as for
20 the proposition that is recited.

As used in this application, the singular form "a," "an," and "the" include plural references unless the context clearly dictates otherwise. For example, the term "an agent" includes a plurality of agents, including mixtures thereof.

25 An individual is not limited to a human being but may also be other organisms including but not limited to mammals, plants, bacteria, or cells derived from any of the above.

Throughout this disclosure, various aspects of this invention can be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the
30 scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical

values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth
5 of the range.

The practice of the present invention may employ, unless otherwise indicated, conventional techniques and descriptions of organic chemistry, polymer technology, molecular biology (including recombinant techniques), cell biology, biochemistry, and immunology, which are within the skill of the art. Such conventional techniques include
10 polymer array synthesis, hybridization, ligation, and detection of hybridization using a label. Specific illustrations of suitable techniques can be had by reference to the example hereinbelow. However, other equivalent conventional procedures can, of course, also be used. Such conventional techniques and descriptions can be found in standard laboratory manuals such as Genome Analysis: A Laboratory Manual Series (Vols. I-IV), Using
15 Antibodies: A Laboratory Manual, Cells: A Laboratory Manual, PCR Primer: A Laboratory Manual, and Molecular Cloning: A Laboratory Manual (all from Cold Spring Harbor Laboratory Press), Stryer, Biochemistry, 4th Ed., 1995, W.H. Freeman, Gait, "Oligonucleotide Synthesis: A Practical Approach" 1984, IRL Press, London, all of which are herein incorporated in their entirety by reference for all purposes.

The practice of the present invention may also employ conventional
20 computational biology methods, software or systems. Basic computational biology methods are described in, e.g., Setubal and Meidanis, et al., 1997, Introduction to Computational Molecular Biology, PWS Publishing Company, Boston; Human Genome Mapping Project Resource Centre (Cambridge), 1998, Guide to Human Genome
25 Computing, 2nd Edition, Martin J. Biship (Editor), Academic Press, San Diego; Salzberg, Searles, Kasif, (Editors), 1998, Computational Methods in Molecular Biology, Elsevier, Amsterdam;

The present invention can employ solid substrates, including arrays in some preferred embodiments. Methods and techniques applicable to polymer (including
30 protein) array synthesis have been described in U.S.S.N 09/536,841, WO 00/58516, U.S. Patents Nos. 5,143,854, 5,242,974, 5,252,743, 5,324,633, 5,384,261, 5,424,186,

5,451,683, 5,482,867, 5,491,074, 5,527,681, 5,550,215, 5,571,639, 5,578,832, 5,593,839, 5,599,695, 5,624,711, 5,631,734, 5,795,716, 5,831,070, 5,837,832, 5,856,101, 5,858,659, 5,936,324, 5,968,740, 5,974,164, 5,981,185, 5,981,956, 6,025,601, 6,033,860, 6,040,193, 6,090,555, and 6,136,269, in PCT Applications Nos. PCT/US99/00730 (International
5 Publication Number WO 99/36760) and PCT/US 01/04285, and in U.S. Patent Applications Serial Nos. 09/501,099 and 09/122,216 which are all incorporated herein by reference in their entirety for all purposes.

Patents that describe synthesis techniques in specific embodiments include U.S. Patents Nos. 5,412,087, 6,147,205, 6,262,216, 6,310,189, 5,889,165, and 5,959,098.

10 Nucleic acid arrays are described in many of the above patents, but the same techniques are applied to polypeptide arrays.

The present invention also contemplates many uses for polymers attached to solid substrates. These uses include gene expression monitoring, profiling, library screening, genotyping, and diagnostics. Gene expression monitoring, and profiling methods can be
15 shown in U.S. Patents Nos. 5,800,992, 6,013,449, 6,020,135, 6,033,860, 6,040,138, 6,177,248 and 6,309,822. Genotyping and uses therefor are shown in USSN 10/013,598, and U.S. Patents Nos. 5,856,092, 6,300,063, 5,858,659, 6,284,460 and 6,333,179. Other uses are embodied in U.S. Patents Nos. 5,871,928, 5,902,723, 6,045,996, 5,541,061, and 6,197,506.

20 The present invention also contemplates sample preparation methods in certain preferred embodiments. For example, see the patents in the gene expression, profiling, genotyping and other use patents above, as well as USSN 09/854,317, Wu and Wallace, Genomics 4, 560 (1989), Landegren et al., Science 241, 1077 (1988), Burg, U.S. Patent Nos. 5,437,990, 5,215,899, 5,466,586, 4,357,421, Gubler et al., 1985, Biochemica et
25 Biophysica Acta, Displacement Synthesis of Globin Complementary DNA: Evidence for Sequence Amplification, transcription amplification, Kwoh et al., Proc. Natl. Acad. Sci. USA 86, 1173 (1989), Guatelli et al., Proc. Nat. Acad. Sci. USA, 87, 1874 (1990), WO 88/10315, WO 90/06995, and 6,361,947.

The present invention also contemplates detection of hybridization between
30 ligands in certain preferred embodiments. See U.S. Pat. Nos. 5,143,854, 5,578,832; 5,631,734; 5,834,758; 5,936,324; 5,981,956; 6,025,601; 6,141,096; 6,185,030; 6,201,639;

6,218,803; and 6,225,625 and in PCT Application PCT/US99/ 06097 (published as WO99/47964), each of which also is hereby incorporated by reference in its entirety for all purposes.

The present invention may also make use of various computer program products
5 and software for a variety of purposes, such as probe design, management of data, analysis, and instrument operation. See, U.S. Pat. Nos. 5,593,839, 5,795,716, 5,733,729, 5,974,164, 6,066,454, 6,090,555, 6,185,561, 6,188,783, 6,223,127, 6,229,911 and 6,308,170.

The present invention may also provide computer software and computer systems
10 for performing the methods of the invention. Computer software products of the invention typically include computer readable medium having computer-executable instructions for performing the logic steps of the methods of the invention. Suitable computer readable medium include floppy disk, CD-ROM/DVD/DVD-ROM, hard-disk drive, flash memory, ROM/RAM, magnetic tapes and etc. The computer executable
15 instructions may be written in any suitable computer language or combination of several languages.

Additionally, the present invention may have preferred embodiments that include methods for providing genetic information over the internet. See provisional application 60/349,546.

20 In one aspect of the invention, methods are provided for nucleic acid analysis. In some embodiments, randomly coupled different nucleic acids are used for affinity capture of target nucleic acids. The captured target nucleic acids (on flat substrates, beads, etc.) are detected using spatially addressable oligonucleotides (such as microarrays, beads). In one embodiment, oligonucleotides are synthesized (or presynthesized and attached on) on
25 beads. Each of the beads may contain at least 2, 4, 6, 10, 50, 100, 1000 different oligonucleotides. The oligonucleotides may be designed to hybridize with target nucleic acids to select specific sequences. A nucleic acid sample is hybridized with the beads. The beads may be washed to reduce nonspecific bindings. The captured nucleic acids (bound nucleic acids) may be eluted, for example, by more stringent hybridization
30 conditions. The eluted nucleic acids may be hybridized to a microarray for detection.

The different oligonucleotides on beads may be synthesized by combinatorial synthesis.

In some embodiments, the oligonucleotides on the beads are designed to select (hybridize) nucleic acids representing certain transcripts (the transcripts themselves or nucleic acids derived from the transcript or their complementary sequences) or nucleic acids representing certain genotyping sites (DNA sequences containing the genotyping sites or nucleic acids derived from such DNA sequences or their complementary sequences).

The selected nucleic acids may be hybridized with microarray chips that detect transcripts or their complements or hybridized with chips that detect SNPs.

In one particularly preferred embodiment, oligonucleotides specific for splicing sites are immobilized (or synthesized on) on beads (each bead may contain different oligonucleotides). The oligonucleotides are used to select splice sites. The oligonucleotides may be, for example, at least 30, 40, 50, 60 bases in length. Nucleic acid sample representing target transcripts may be hybridized with the beads. The target nucleic acids representing the splicing sites may be selected using the beads. The selected target nucleic acids may be hybridized with a microarray designed to interrogate the splicing sites to detect the forms of transcripts (forms of exon combination). The selection step may reduce cross hybridization.

In one embodiment, one set of beads are used to purify (select) one particular junction structure (e.g., exons 1, 2 or exons 2, 3 in a 3 exon gene). The purified nucleic acid from the first set is labeled with one color (e.g., fluorescent label)(C1). A second set is used to purify another set of junction structure (e.g., exons 1, 3 or 3, 4). The second set is labeled with a second color (C2). The resulting labeled nucleic acids are hybridized with a microarray that detects exons 1, 2, 3. The two color signals may be used to analyze relative abundance of alternatively splice transcripts. For example, the ratio C1/C2 may be indicative of relative abundance of different exon combinations.

Definitions


“Alkyl” refers to a straight chain, branched or cyclic chemical group containing only carbon and hydrogen. Alkyl groups include, without limitation, ethyl, propyl, butyl, pentyl, cyclopentyl and 2-methylbutyl. Alkyl groups are unsubstituted or substituted

with 1 or more substituents (e.g., halogen, alkoxy, amino, S).

“Aryl” refers to a monovalent, unsaturated aromatic carbocyclic group. Aryl groups include, without limitation, phenyl, naphthyl, anthryl and biphenyl. Aryl groups are unsubstituted or substituted with 1 or more substituents (e.g. halogen, alkoxy, amino).

5 “Alkoxy” refers to a chemical group of the structure $((CH_2)_nO(CH_2)_m)_x$, wherein n is an integer ranging from 0 to about 10, and m is an integer ranging from 0 to about 10, wherein both m and n cannot simultaneously be 0 and X is an integer from 1 to 4.

According to one aspect of the present invention, a cyclic silane is presented having the the formula




wherein R_1 , R_2 , R_3 and R_4 are independently alkyl, substituted alkyl, aryl or alkoxy and X and Y are independently a bond, S, NR_5 , wherein R_5 is H or alkyl, or O.

Preferably, X and Y are O. R_1 , R_2 , R_3 and R_4 are preferably C_1 to C_{10} alkyl. More preferably, R_1 , R_2 and R_4 are ethyl and R_3 is propyl. In another preferred embodiment of the present invention, R_1 and R_2 are ethyl and R_4 is methyl.

15 In still other preferred embodiments, R_1 and R_2 are alkoxy. More preferably, R_1 and R_2 are $(CH_2CH_2O)_n$ wherein n is 1-4 and X and Y are bonds.


In a particularly preferred embodiment of the present invention, a cyclic silane having the following formula is presented:

20



In another aspect of the present invention, a cyclic silane having the following formula is presented:

5




wherein R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 and R_8 are independently alkyl, functionalized alkyl, aryl or alkoxy and X is a bond, S , NR_5 , wherein R_5 is H or alkyl, or O .

In accordance with one aspect of the present invention, X is preferably O . R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 and R_8 are preferably C_1 to C_{10} alkyl. More preferably, R_4 , R_5 , R_6 , R_7 and R_8 are methyl and R_1 is ethyl, R_2 is propyl and R_3 is propyl. In another preferred embodiment of the present invention, R_4 , R_5 , R_6 , R_7 , and R_8 are ethyl.

In accordance with one aspect of the present invention, R_1 is preferably alkoxy. More preferably, R_1 is $(CH_2CH_2O)_n$ wherein n is 1-4 and X is a bond.


In a particularly preferred embodiment of the present invention, a cyclic silane having the following formula is presented:



In accordance with one aspect of the present invention, a method of silanating substrates is presented. The method comprises vapor deposition of the silanation reagent
 5 onto a substrate. According to the present invention, the substrates are preferably beads, particles, fibers or wafers. Glass wafers are particularly preferred. Vapor deposition of the reagents involves exposure of the substrate to the reagent in a vacuum oven. Prior to the instant invention, it was believed that many silane reagents were not low boiling enough to allow vapor deposition without thermal decomposition of the silane. However,
 10 it has been discovered in accordance with one aspect of the present invention that cyclic silanes frequently have lower boiling points than their linear counter parts. The lower boiling points of these compounds makes them amenable to vapor deposition. However, the cyclic silanes of the instant invention may also be used in standard bath deposition or spin coating procedures.

15 In accordance with another aspect of the present invention, compositions of matter are presented, the compositions comprising substantially pure cyclic silane compounds as disclosed in the instant application. The term "substantially pure" as employed in accordance with the instant invention means a compound which is at least approximately 80% pure. Preferably, the composition of matter comprising a cyclic
 20 silane is at least approximately 90% pure. More preferably, the cyclic silane is at least approximately 95% pure. Depending on the temperature and pressure, the substantially pure cyclic silane will exist as a solid, liquid or gas. .


In another aspect of the present invention, cyclic silanes are presented having the formula



wherein R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , and R_9 are alkyl, substituted alkyl, aryl, or alkoxy; and T , U , V , X , Y , and Z are O , S , NHR_{10} , wherein R_{10} is H , alkyl, substituted alkyl, or aryl.

- 5 Preferably, according to the present invention, R_1 , R_2 , and R_6 are ethyl, R_4 , R_5 , R_7 and R_8 are methyl and R_3 and R_9 are propyl $(-CH_2-)_3$; and T , U , V , X , Y , and Z are O .


In yet another aspect of the present invention, a cyclic silane is presented having the formula:



- 10 wherein R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , R_{10} and R_{11} are alkyl, substituted alkyl, aryl, or alkoxy and T , U , W , X , Y , and Z are O , S , NHR_{12} , wherein R_{12} is H , alkyl, substituted alkyl, or aryl.

Preferably, in accordance with this aspect of the present invention, T, U, W, X, Y and Z are O; and R₁, R₃, R₄, R₅, R₆, R₇, R₈ are ethyl, R₂ and R₁₁ are propyl (-CH₂)₃, and R₉ and R₁₀ are methyl.

In accordance with another aspect of the present invention, a cyclic silane is
5 presented having the formula:



wherein R₁, R₂, R₃, R₄, R₅, R₆, R₇, and R₈ are alkyl, substituted alkyl, aryl, or alkoxy and T, W, X, and Y are O, S, NHR₁₁, wherein R₁₁ is H, alkyl, substituted alkyl, or aryl.


10 Preferably, according to the present invention, R₆ and R₇ are methyl, R₁ and R₅ are propyl (-CH₂)₃, R₂, R₃, R₄, and R₈ are ethyl and T, W, X, and Y are O.

In accordance with another aspect of the present invention, a cyclic silane is presented having the formula:




Preferably, according to the present invention, R₄, R₁₁, and R₁₅ are propyl (-CH₂-CH₂-CH₃), R₁, R₂, R₃, R₅, R₆, R₇, R₈, R₉, R₁₀, R₁₂, R₁₃, R₁₄ are ethyl, and A, B, T, U, V, X, Y and Z are O.

10




Preferably, according to the present invention, R₁, R₂ and R₃ are propyl (-CH₂-)₃, R₄, R₅, R₆, R₇, R₈, and R₉ are ethyl and T, U, W, X, Y, and Z are O.

A similarly structured cyclic silane is shown below:




wherein R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, and R₉, are alkyl, substituted alkyl, aryl, or alkoxy and T, U, W, X, Y and Z are O, S, NHR₁₀, wherein R₁₀ is H, alkyl, substituted alkyl, or aryl. Preferably, according to the present invention, R₁, R₂ and R₃ are propyl (-CH₂-)₃, R₄, R₅, R₆, R₇, R₈, and R₉ are ethyl and T, U, W, X, Y, and Z are O.

10 In yet another aspect of the present invention, a cyclic silane with the formula below is shown:




15 wherein R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, and R₉, are alkyl, substituted alkyl, aryl, or alkoxy and T, U, W, X, Y and Z are O, S, NHR₁₀, wherein R₁₀ is H, alkyl, substituted alkyl, or aryl. Preferably, according to the present invention, R₂ and R₃ are propyl (-CH₂-)₃, R₁, R₈ and R₉ is methyl, R₄, R₅, R₆, R₇ are ethyl and T, U, W, X, Y, and Z are O.

In still another aspect of the present invention, a cyclic silane having the following formula is shown:




- 5 wherein R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , and R_9 , are alkyl, substituted alkyl, aryl, or alkoxy and T, U, W, X, Y and Z are O, S, NHR_{10} , wherein R_{10} is H, alkyl, substituted alkyl, or aryl. Preferably, according to the present invention, R_2 and R_3 are propyl ($-CH_2-$)₃, R_1 , R_8 and R_9 is methyl, R_4 , R_5 , R_6 , R_7 are ethyl and T, U, W, X, Y, and Z are O.

- In accordance with another aspect of the present invention, the following cyclic
 10 silane is disclosed:




wherein R_1 is alkyl and repeating polymeric units are designated by n which is 5 to 10,000. R_1 is an alkane, substituted alkane, or alkoxy.

In another embodiment of the present invention, a cyclic silane is presented
 5 having the formula




- wherein $R_1, R_2, R_3, R_4, R_5, R_6, R_7, R_8,$ and R_9 , are alkyl, substituted alkyl, aryl, or alkoxy and T, U, V, X, Y and Z are O, S, NHR_{10} , wherein R_{10} is H , alkyl, substituted alkyl, or aryl. Preferably, according to the present invention R_3, R_4, R_5 and R_6 are methyl, R_1 and
- 5 R_2 are propyl $(-CH_2)_3$, $R_7, R_8,$ and R_9 are ethyl and T, U, V, X, Y and Z are O .

In accordance with yet another aspect of the present invention, a cyclic silane having the formula set forth below is presented:




wherein $R_1, R_2, R_3, R_4, R_5, R_6, R_7, R_8, R_9$, and R_{10} are alkyl, substituted alkyl, aryl, or alkoxy and T, U, V, X, Y and Z are O, S, NHR_{11} , wherein R_{11} is H, alkyl, substituted alkyl, or aryl. Preferably, according to the present invention, R_1, R_4, R_5, R_6, R_7 and R_8 are ethyl, R_3 and R_9 are propyl, R_2 and R_{10} are methyl, and T, U, V, X, Y, and Z are O.

5 In accordance with yet another aspect of the present invention, a polymeric cyclic silane is presented have the following formula:




wherein $R_1, R_2, R_3, R_4, R_5, R_6$, and R_7 are alkyl, substituted alkyl, aryl, or alkoxy and W, X, Y and Z are O, OH, S, NHR_8 , wherein R_8 is H, alkyl, substituted alkyl, or aryl. In the above, polymeric cyclic structure n represents the repeating units of the polymer. n is an integer is from 5 to 10,000. Preferably, according to the present invention, R_4 is propyl, R_1, R_2, R_3, R_5, R_6 , and R_7 are ethyl and W, X, Y and Z are O or OH.

15 In yet another aspect of the present invention, a cyclic silane having the following formula is presented:



wherein R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , and R_7 are alkyl, substituted alkyl, aryl, or alkoxy and W , X , Y and Z are O, OH, S, NHR_8 , wherein R_8 is H, alkyl, substituted alkyl, or aryl and n is an integer between 5 and 10,000. Preferably, according to the present invention, R_4 is propyl, R_1 , R_2 , R_3 , R_5 , R_6 , and R_7 are ethyl and W , X , Y and Z are O or OH.


In still another embodiment of the present invention, the following cyclic, polymeric silane structure is presented.




wherein R_1 , R_2 , R_3 , R_4 and R_5 are alkyl, substituted alkyl, aryl, or alkoxy and W , X , Y and Z are O, OH, S, NHR_6 , wherein R_6 is H, alkyl, substituted alkyl, or aryl and m is an integer between 5 and 10,000. Preferably, according to the present invention, R_1 is propyl ($-CH_2-$)₃, R_1 , R_2 , R_3 , and R_5 are ethyl and W , X , Y and Z are O or OH.

EXAMPLES

According to one aspect of the present invention, it has been discovered that 2-(2-hydroxyethyl)-N-(3-triethoxysilylpropyl)amine ("Bis") and N-(2-hydroxyethyl)-N,N-bis(3-trimethoxysilylpropyl)amine ("Bis-B") may, under some circumstances, have cyclic structures. The linear structures of Bis and Bis-B are shown below:



Bis



Bis-B

The synthesis and use of silanes in the fabrication of arrays, including high density nucleic acid arrays, is described for example in U.S. Patent Nos. 6,262,216, 6,486,287 and 6,429,275, each of which are incorporated herein by reference. Bis-B are typically synthesized by treatment of the corresponding aminosilane with ethylene oxide. (See 6,486,287 patent). These reagents are supplied as 65% solutions in either ethanol (Bis) or methanol (Bis-B) to prevent intermolecular cyclization, since the hydroxyl functionality could in principle displace a silyl alkoxy group. Analysis of the Bis and Bis-B reagents reveals that these compounds may have cyclic structures under certain circumstances as described below.

Spectra

Interpretation of the NMR spectra of Bis and Bis-B are complicated somewhat by the presence of the alcohol solvent in which they are kept and also by varying amounts of 2-hydroxyethanol (Bis) or methoxyethanol (Bis-B). The latter components probably result from the reaction of either ethanol or methanol with ethylene oxide.



The ^{13}C NMR spectrum of Bis (Figure 1) reveals two resonances that can be
 5 attributed to ethanol, and four others that can be attributed to 2-ethoxyethanol. The
 remaining seven resonances are consistent with the seven unique carbon atoms of Bis
 (note the structural plane of symmetry). The corresponding ^1H NMR spectrum (Figure 2)
 shows the expected five CH_2 groups, two of which integrate to four protons due to the
 symmetry element. Interestingly, the methyl region near 1.1 ppm seems to indicate a
 10 mono-alkoxy silane as opposed to a tri-alkoxy silane. This could arise if both 2-
 hydroxyethyl groups displaced ethoxy groups in an intramolecular manner. If only a
 single ethoxy group was displaced, the structure would lose symmetry and two additional
 ^{13}C NMR resonances would be expected, as well a more complex ^1H NMR pattern.

The ^{13}C NMR spectrum of Bis-B (Figure 3) reveals one resonance for methanol,
 15 and three small resonances that can be attributed to methoxyethanol. Apart from these
 signals, the spectrum shows ten other resonances. This number of unique signals would
 be consistent with a cyclic structure due to intramolecular displacement of a methoxy
 group by the 2-hydroxyethanol moiety. In contrast, the symmetrical, non-cyclized form
 of Bis-B would be expected to show a total of only six resonances. The ^1H NMR
 20 spectrum of Bis-B (Figure 4) is not well defined, in contrast to the corresponding
 spectrum of Bis. Whereas the doubly-cyclized form of Bis retains symmetry, the
 cyclized form of Bis-B does not, and therefore complex overlapping signals would be
 expected. Although the ^1H NMR spectrum of Bis-B reveals three signals near 3.5 ppm,
 the integration is not in perfect agreement with a cyclized structure (expect methanol +
 25 $9\text{H} + 6\text{H}$).

GC/MS

Gas chromatography and mass spectrometry were also carried out with Bis and
 Bis-B. When considered together with the solution-phase NMR data, the results are
 informative and further suggest that both Bis and Bis-B exist in a cyclic form.

The GC/MS ion chromatogram for Bis (Figure 5) shows two primary peaks with retention times of 13.85 and 16.16 minutes, at about a 3:1 height ratio, respectively. The MS of the larger peak (13.85 minutes) shows a parent ion with a mass of 217 m/z and fragments at 202, 188 and 172 m/z. This mass and fragmentation pattern is consistent with a bicyclic silane structure. The fragments correspond to loss of CH₃, CH₃CH₂, and CH₃CH₂O. The MS of the smaller peak (16.16 minutes) shows a parent ion with a mass of 261 m/z and fragments at 232, 218, 202, 188 and 172 m/z. This mass and fragmentation pattern is consistent with a bicyclic silane structure that also possesses a 2-ethoxyethanol group (substituted for ethanol). The fragments correspond to loss of CH₃CH₂, CH₃CH₂O, CH₃CH₂OCH₂CH₂ and CH₃CH₂OCH₂CH₂O. The two early-eluting peaks (2.73 and 3.59 minutes) correspond to ethoxyethanol and the dichloromethane diluent, respectively.

It should be noted that alternative interpretations of the mass spectra are possible. In addition, the fragmentation of the apparent minor component of the Bis silane ion chromatogram is explained equally well by “double” ethylene oxide addition during chemical synthesis. However, observations of changes in the ion chromatogram of Bis-B upon addition of 2-methoxyethanol (see below), and the presence of substantial levels of the corresponding 2-ethoxyethanol in the Bis silane preparation, suggest that the minor component is instead the 2-ethoxyethanol substituted silane.

The GC/MS ion chromatogram for Bis-B (Figure 6) is somewhat more complicated than the one for Bis, showing 2-3 unidentified peaks. However, as with Bis, the ion chromatogram shows two primary peaks with retention times of 16.26 and 17.74 minutes whose intensities range between 10:1 and 3:1 depending on the particular lot. The MS of the larger peak (16.26 minutes) shows a parent ion with a mass of 353 m/z and fragments at 322 and 204 m/z. This mass and fragmentation pattern is consistent with a cyclic silane structure. The fragments correspond to loss of CH₃O and (CH₃O)₃SiCH₂CH₂. The MS of the smaller peak (17.74 minutes) shows a parent ion with a mass of 397 m/z and fragments at 366, 322, 248 and 204 m/z. This mass and fragmentation pattern is consistent with a cyclic silane structure that also possesses a 2-methoxyethanol group (substituted for methanol). The fragments correspond to loss of CH₃O, CH₃OCH₂CH₂O, (CH₃O)₃SiCH₂CH₂ and possibly

$\text{CH}_3\text{OCH}_2\text{CH}_2\text{O}(\text{CH}_3\text{O})_2\text{SiCH}_2\text{CH}_2$. The two early-eluting peaks (<2 minutes) correspond to methoxyethanol and the dichloromethane diluent.

As with Bis silane, it should be noted that alternative interpretations of the mass spectra are possible. Also as indicated above, addition of 2-methoxyethanol to the Bis-B silane resulted in an increase in the relative height of the peak at 17.74 minutes, demonstrating that 2-methoxyethanol can readily displace silane methoxy groups and that this 397 m/z peak does not result from double ethylene oxide addition (the m/z would also be 397 if Bis-B reacted with a second unit of ethylene oxide).

Three-Dimensional Structure of Bis and Bis-B

The proposed three-dimensional structures of Bis and Bis-B are depicted in Figure 7, after MOPAC energy minimization. These structures are consistent with the analytical data presented earlier.